Ann: Immutep Reports Positive Data from its TACTI-002 ph 2 trial, page-4

OS for 2nd line HNSCC for efti and keytruda is 12.6 months while keytruda monotherapy is i think 8.4 months. 5 CRs for 2nd line HNSCC is huge.

To put it in perspective, keytruda as a 1st line treatment for HNSCC has an OS of approx 12 months- so keytruda 1st line results are comparable to efti + keytruda 2nd line results, with 2nd line patients obviously having more progressed tumours and tumour resistance.

This bodes well for Tacti 003, where keytruda is going up against the efti + keytruda combo - wouldn't be unreasonable to expect a pretty big jump in OS for 1st line patients when treated with the combo compared to the monotherapy. If the median OS can hit 18-20 months or so, consider it game on.

Strong results also in 1st line NSCLC, but we need the data on the expansion cohort. Can't see why it won't be comparable to results to date.